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Abstract
Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deﬁciency
(ORD) present with disordered sex development and glucocorticoid deﬁciency. This is due to disruption
of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key
role in glucocorticoid and sex steroid synthesis. POR also transfers electrons to all major drug-
metabolizing CYP enzymes, including CYP3A4 that inactivates glucocorticoid and oestrogens.
However, whether ORD results in impairment of in vivo drug metabolism has never been studied.
Design: We studied an adult patient with ORD due to homozygous POR A287P, the most frequent POR
mutation in Caucasians, and her clinically unaffected, heterozygous mother. The patient had received
standard dose oestrogen replacement from 17 until 37 years of age when it was stopped after she
developed breast cancer.
Methods: Both subjects underwent in vivo cocktail phenotyping comprising the oral administration of
caffeine, tolbutamide, omeprazole, dextromethorphan hydrobromide and midazolam to assess the ﬁve
major drug-metabolizing CYP enzymes. We also performed genotyping for variant CYP alleles known
to affect drug metabolism.
Results: Though CYP enzyme genotyping predicted normal or high enzymatic activities in both
subjects, in vivo assessment showed subnormal activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4
in the patient and of CYP1A2 and CYP2C9 in her mother.
Conclusions: Our results provide in vivo evidence for an important role of POR in regulating drug
metabolism and detoxiﬁcation. In patients with ORD, in vivo assessment of drug-metabolizing activities
with subsequent tailoring of drug therapy and steroid replacement should be considered.
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Introduction
P450 oxidoreductase (POR) deﬁciency (ORD) is a
variant of congenital adrenal hyperplasia that is not
caused by mutations in a steroidogenic enzyme
itself, but in the co-factor enzyme POR (1–3).P O R
facilitates electron transfer from NADPH to keyenzymes
involved in glucocorticoid and sex steroid synthesis,
17a-hydroxylase/17,20 lyase (CYP17A1), CYP21A2
(21-hydroxylase) and CYP19A1 (aromatase). There-
fore, mutant POR results in clinical presentation with
disordered sex development (DSD) and glucocorticoid
deﬁciency (1, 2). Intriguingly, individuals of both sexes
may present with DSD, i.e. 46,XX DSD and 46,XY DSD.
While undervirilization of affected male individuals is
readily explained by insufﬁcient sex steroid synthesis,
virilization in girls is thought to be consequent to the
exaggerated activity of an alternative pathway towards
androgen synthesis that is active in fetal life and ceases
activity shortly after birth (1). Individuals affected by
ORD also often present with skeletal malformations,
most likely consequent to impaired synthesis of
cholesterol (4, 5) and retinoic acid metabolism (6),
both of which play a crucial role in the regulation of
fetal bone development and growth (5, 7).
In addition to facilitating steroid and sterol synthesis,
POR provides electrons to all major drug-metabolizing
cytochrome P450 (CYP) enzymes, and thus it is
conceivable that mutant POR will also disrupt drug
and xenobiotic metabolism (Fig. 1). Five CYP enzymes
(CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4)
are responsible for the metabolism of more than 80% of
all drugs (8). CYP3A4 represents the major player
involved in the metabolism of more than half of existing
drugs, notably also in the inactivation of steroid
hormonesincludingglucocorticoidsandsexsteroids(9).
A functional impact of sequence variants in the POR
gene on hepatic drug metabolism by POR sequence has
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and a recent in vivo study in healthy individuals (14).
However, the signiﬁcance of mutant POR for human
drug metabolism has not been studied yet in the clinical
context of ORD. Here, we have studied the activities of
the ﬁve major drug-metabolizing CYP enzymes in two
individuals carrying the POR variant A287P, the most
frequently observed disease-causing POR mutation in
Caucasians.
Subjects and methods
Subjects
A 48-year-old patient with congenital adrenal
hyperplasia due to ORD and her clinically unaffected
72-year-old mother participated in the study. The
neonatal and pubertal presentation of this patient has
been reported elsewhere (J Idkowiak, unpublished
observations); in brief, she presented at birth with
severely virilized external genitalia, i.e. 46,XX DSD, and
was wrongly assigned to the male gender. At the age of
5 years, sex reassignment was prompted by the birth of
a virilized sister. Owing to lack of spontaneous pubertal
development, puberty had been induced at the age of
17 years by equine oestrogens and progesterone.
Detailed assessment at the age of 24 years revealed
elevated serum progesterone and 17OH-progesterone,
low serum androgens, partial adrenal insufﬁciency with
an impaired cortisol response to ACTH stimulation and
clinical and radiological evidence of mild dysmorphic
features (low set ears, clinodactyly, camptodactyly and
brachydactyly). Blood pressure was elevated on
repeated measurements (systolic 140–160 mmHg and
diastolic 90–95 mmHg).
Oestrogen/progestin replacement was continued
until the age of 37 years, when she was diagnosed
with breast cancer, despite a negative family history. The
tumour was 3 cm in diameter, with a mixed histological
picture featuring foci of ductal adenocarcinoma as well
as stromal myxoid changes; tumour tissue was negative
for oestrogen and progesterone receptor staining and
Her-2/neu ampliﬁcation. Oestrogen/progestin replace-
ment was stopped post surgical follow-up until her
current age of 49 years did not reveal a recurrence.
Methods
POR and CYP enzyme genotyping To ascertain the
diagnosis of ORD, genetic analyses were performed after
obtaining written informed consent and with approval
of the South Birmingham Research Ethics Committee.
The coding region of the POR gene (GeneID 5447) was
ampliﬁed as previously described (1),e m p l o y i n g
genomic DNA from the patient and her mother.
In addition to POR sequencing, we performed
genotyping for common variant alleles of the genes
encoding the major drug-metabolizing CYP enzymes
since such sequence variants have been shown to
contribute to an individual’s drug response. Analyses
included the determination of variant alleles *2 and *3
of CYP2C9 (15), allele *2 of CYP2C19 (16) and alleles
*3, *4, *5, *6 and the gene duplication of CYP2D6 (17).
*n denotes the individual allele as decided by the Human
CYP Allele Nomenclature Committee (http://www.
cypalleles.ki.se/).
In vivo low dose cocktail phenotyping Both subjects
underwent in vivo phenotyping to assess the activities of
the major hepatic drug-metabolizing CYP enzymes
carried out after obtaining informed consent and with
approval of the ethics committee of the University
Hospital Cologne. Low doses of validated substrates
selective for each of the ﬁve major drug-metabolizing
CYP enzymes were orally administered simultaneously
as a ‘cocktail’ (Table 1), thereby allowing for estimation
of several metabolic pathways in a single assessment
(18). Phenotyping was performed under in-patient
conditions. After an overnight fast, blood samples
were drawn before and 1, 3, 6 and 24 h after the oral
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Figure 1 P450 oxidoreductase (POR) transfers electrons to all
microsomal cytochrome P450 (CYP) enzymes. POR thereby
impacts on the function of three major metabolic systems involving
microsomal CYP enzymes: steroid synthesis in adrenal glands and
gonads, cholesterol synthesis (e.g. in developing bone) and
metabolism of steroids, drugs and other xenobiotics, mainly in the
liver; drug-metabolizing microsomal CYP enzymes: CYP1A2,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4; steroidogenic micro-
somal CYP enzymes: CYP17A1 (17a-hydroxylase/17,20 lyase),
CYP21A2 (21-hydroxylase) and CYP19A1 (aromatase); micro-
somal CYP enzymes involved in sterol synthesis and metabolism:
CYP51A1 (14a-lanosterol demethylase) and SQLE (squalene
epoxidase); microsomal CYP enzymes involved in retinoic acid
metabolism: CYP26A1, CYP26B1 and CYP26C1.
920 D Tomalik-Scharte and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163
www.eje-online.orgadministration of 150 mg caffeine, 125 mg tolbuta-
mide, 20 mg omeprazole, 30 mg dextromethorphan
hydrobromide and 2 mg midazolam at 0900 h
(Table 1). Plasma concentrations of the probe drugs
and their metabolites were determined by liquid
chromatography/tandem mass spectrometry as pre-
viously described (19). The results of the cocktail
phenotyping were projected on to the reference range
obtained in normal controls (CYP1A2: nZ768 (20);
CYP2C9: nZ26 (21); CYP2C19: nZ153, estimated
according to (22); CYP2D6: nZ51, unpublished
in-house data; CYP3A4: nZ66 (23)).
Results
ORD was conﬁrmed by POR sequencing, which revealed
subjects 1 and 2 as homozygous and heterozygous
carriers respectively of the c.852G/C (g.29,556G/C)
mutation in exon 8 of the POR gene, encoding for an
amino acid change from alanine to proline in position
287 of the POR protein, p.A287P.
Both subjects had CYP2C19 genotypes indicative of a
rapid metabolizer phenotype, i.e. high enzymatic
activity, and their CYP2C9 genotypes were predictive
of normal activity (Table 2). CYP2D6 genotyping found
CYP2D6 g e n ed u p l i c a t i o ni ns u b j e c t1( p a t i e n t ) ,
consistent with an ultrarapid metabolizer phenotype,
while variant alleles identiﬁed in subject 2 (mother)
predicted a rapid metabolizer phenotype (Table 2).
However, despite CYP genotyping results predictive of
normal to high enzymatic activities, invivodrug cocktail
phenotyping revealed low activities of all tested CYP
enzymes in both subjects (Fig. 2). The patient and her
mother had similarly decreased activities of CYP1A2
(oral caffeine clearance (ml/min per kg body weight);
subject 1, 0.25; subject 2, 0.35) and CYP2C9 (plasma
tolbutamide concentration 24 h post dose (mg/ml);
subject 1, 13.9; subject 2, 7.8), clearly below the 5th
percentile of a normal reference population (Fig. 2).
Also CYP2C19 activity was similarly low in both
subjects (plasma omeprazole/5-hydroxyomeprazole 4 h
post dose; subject 1, 2.79; subject 2, 2.66), albeit still
within the lowest quartile of the normal reference range
(Fig. 2). However, with regards to CYP2D6 and
CYP3A4, we observed lower metabolic capacities for
subject 1 whowas homozygous for POR A287P than for
subject 2 who carried only one mutant POR A287P
allele. Subject 1 showed clearly subnormal conversion
of the probe drugs, whereas observed metabolic
capacities of CYP2D6 and CYP3A4 for subject 2 still
varied within the lowest normal range (CYP2D6:
plasma dextromethorphan/dextrorphan 3 h post dose;
subject 1, 5.05; subject 2, 0.68; CYP3A4: oral
midazolam clearance (L/hl); subject 1, 10.7; subject 2,
39.7) (Fig. 2).
Discussion
Here, we have provided in vivo evidence for impaired
drug metabolism as a consequence of mutant POR.
In vivo cocktail phenotyping revealed grosslydiminished
activities of drug-metabolizing CYP enzymes in the two
subjects carrying the POR A287P mutation, a disease-
causing POR variant most frequently found in Cauca-
sians (1, 2). However, it is remarkable that even
heterozygosity for this allele was sufﬁcient to clearly
Table 1 In vivo low dose drug cocktail phenotyping for assessment of drug-metabolizing cytochrome P450 (CYP)
enzymes including selective substrates employed, respective doses and phenotyping parameters.
Drug-metabolizing
CYP enzymes Drug Dose (mg) Phenotyping parameter (unit)
CYP1A2 Caffeine 150 Oral caffeine clearance (ml/min per kg body
weight)
CYP2C9 Tolbutamide 125 Plasma concentration of tolbutamide 24 h post
dose (mg/ml)
CYP2C19 Omeprazole 20 Ratio of the molar plasma concentrations of
omeprazole over 5-hydroxyomeprazole 3 h
post dose (K)
CYP2D6 Dextromethorphan
hydrobromide
30 Ratio of the molar plasma concentrations of
dextromethorphan over dextrorphan 3 h
post dose (K)
CYP3A4 Midazolam 2 Oral midazolam clearance (L/hl)
Table 2 Results of cytochrome P450 (CYP) genotyping in the
patient with P450 oxidoreductase (POR) deﬁciency (ORD) due to
homozygous POR A287P (subject 1) and her clinically unaffected,
heterozygous mother (subject 2), listing the identiﬁed variant alleles
(*) of CYP2C9, CYP2C19 and CYP2D6 previously described to
affect enzymatic activity.
Predicted drug metabolizer phenotype
(according to variant CYP allele genotype)
Drug-metabolizing
CYP enzymes
Subject 1
(A287P/A287P)
Subject 2
(A287P/WT)
CYP2C9 Intermediate (*1/*2) Rapid (*1/*1)
CYP2C19 Rapid (*1/*1) Rapid (*1/*1)
CYP2D6 Ultrarapid (2!*2/*1) Rapid (*1/*1)
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metabolizing CYP enzymes, as demonstrated in the
patient’s mother. Of note, the clinically observed drug-
metabolizing CYP enzyme activities in the two subjects
were severely decreased despite CYP genotyping results
predictive of normal to high activities. This suggests that
the effect of genetic variation in POR on interindividual
variability in drug metabolism may be at least as
important as that of variant CYP alleles.
We have previously shown that POR A287P
differentially affects the activity of electron-accepting
steroidogenic CYP enzymes, namely a preferential
inhibition of 17-hydroxylase over 21-hydroxylase, as
demonstrated in vitro and also in vivo by increased
urinary excretion of corticosterone over cortisol metab-
olites, causing a relative accumulation of steroids with
mineralocorticoid-like activity (24). The clinical signi-
ﬁcance of this ﬁnding is clearly reﬂected by the clinical
phenotype of the current patient who presented with
manifest arterial hypertension at the age of 24 years,
most likely a consequence of mild mineralocorticoid
excess. In addition, it has been shown that POR A287P
does not result in any inhibition of CYP19A1 activity
(25), further highlighting the differential effects of this
mutant. Thus, it is entirely possible that distinct POR
variants may have only modest effects on steroidogenic
CYPenzymes but could severely disrupt drug-metaboliz-
ing CYP enzymes.
POR is a highly polymorphic gene with more than
140 documented sequence variants in the POR-coding
region, including 40 present on more than 1% of alleles
(26). A number of in vitro studies and a recent in vivo
studyhaveattempted toaddress thecorrelationbetween
genetic variation in POR and drug-metabolizing CYP
enzyme activities (10–14, 27). A recent study demon-
strated reduced in vitro CYP3A4 activity due to POR
A287P (13). However, another study demonstrated
complete abolishment of CYP1A2 and CYP2C19
activities by POR A287P in vitro (10), which contrasts
with our in vivo ﬁnding of clearly diminished albeit still
detectable CYP1A2 and CYP2C19 activities in our
patient carrying homozygous A287P. This emphasizes
that in vitro assays are valuable, but will not always
correctly reﬂect complex systems such as the CYP–POR
drug-metabolizing complex, where genetic variants
within more than one gene may impact on the
enzymatic activities observed in vivo. Obviously, we
cannot exclude that the observed reduction in drug-
metabolizing enzyme activities in our two subjects of
similar familial genetic background could be due to
another, hitherto not yet identiﬁed genetic variation.
However, the signiﬁcance of POR for drug metabolism
was also indicated by previous rodent-based studies
analysing liver-speciﬁc Por deletion, demonstrating
disruption of cholesterol and bile acid metabolism (28)
and reduced activation of the chemotherapeutic pro-
drug cyclophosphamide (29). Another possible caveat is
that the heterozygous mother was 78 years of age, and
the drug metabolism proﬁle was compared with CYP
genotype-matched controls but could not be directly
compared with age-matched controls as such data are
notavailable.However,thereisnogenerallossofhepatic
CYP activity with age, as previously shown in vitro (30)
and in vivo (31), which would explain the uniform low
activity in the mother.
Of note, our patient developed breast cancer at the
very early age of 37 years, despite a negative family
history. It is tempting to speculate about the possible
contribution of mutant POR to the development of this
early onset breast cancer. CYP3A4 is the major enzyme
involved in the inactivation of steroid hormones
including glucocorticoids and sex steroids (9), and we
found that in vivo CYP3A4 activity was grossly reduced
in our patient, who had received standard dose
oestrogen replacement for 20 years prior to being
diagnosed with breast cancer. Impairment of CYP3A4
activity, as documented in our patient, will have
undoubtedly resulted in delayed breakdown of and
increased exposure to oestrogen, a well-known risk
factor for breast cancer. CYP3A4 activity is known to
display broad interindividual variability and, in contrast
to other drug-metabolizing CYP enzymes, convincing
associations between variant CYP3A4 alleles and
observed in vivo enzymatic activity are lacking (32).
Thus, variant POR might be a more important
modulator of CYP3A4 function than genetic variation
in CYP3A4 itself.
Our ﬁnding of grossly impaired drug-metabolizing
activities in our patient despite carrying variant CYP
alleles predictive of high enzymatic activities inevitably
poses the question whether this should alter clinical
management. We feel that based on our results, low
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
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Figure 2 In vivo low dose cocktail phenotyping for assessment of
drug-metabolizing CYP enzyme activities in P450 oxidoreductase
deﬁciency. The results of the cocktail phenotyping in subject 1
(patient, A287P/A287P) and subject 2 (mother, A287P/WT)
projected on to the reference range obtained in normal controls,
with the boxes representing the 25th to 75th percentile and the
whiskers indicating 5th and 95th percentiles respectively. Results
are represented as multiples of the median enzyme activity
observed in the respective normal reference cohorts (for details,
see the Methods section).
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procedure, should be considered in all patients with
CAH caused by ORD to determine whether future drug
therapy and, importantly, also steroid replacement
therapy including glucocorticoid and sex steroids
require individually tailored dosing.
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